Meningococcal Group B Vaccine for Gonorrhea
This trial tests whether the group B meningitis vaccine protects from Neisseria gonorrhoeae infection. Approximately 120-140 participants will be enrolled and receive 2 doses of vaccine.
1 Primary · 3 Secondary · Reporting Duration: between 1 and 10 days after N. gonorrhoeae inoculation (between study day 58 and study day 123)
Side Effects for
1 Treatment Group
1 of 1
140 Total Participants · 1 Treatment Group
Primary Treatment: Meningococcal Group B Vaccine · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18 - 35 · Male Participants · 34 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many participants has this research project attracted thus far?
"Indeed, the records on clinicaltrials.gov indicate that recruitment is still ongoing for this medical trial which had its inception on April 18th 2022 and has since been updated as recently as May 19th 2022. The current goal of the study is to acquire 140 participants from a single location." - Anonymous Online Contributor
Is my profile fitting of the criteria for participation in this research endeavor?
"The prerequisites for this medical survey are a confirmed diagnosis of gonorrhea and an age between 18 to 35 years. At present, 140 subjects are being accepted into the study." - Anonymous Online Contributor
Does this experiment currently accept participants?
"According to clinicaltrials.gov, this trial is accepting participants and has been available for enrollment since April 18th 2022. The record was recently renewed on May 19th of the same year." - Anonymous Online Contributor
Are those aged over 40 being included in the current trial?
"This trial requires participants to be between 18 and 35 years old." - Anonymous Online Contributor
Has the Food and Drug Administration certified Meningococcal Group B Vaccine as safe?
"There is empirical evidence suggesting the safety of Meningococcal Group B Vaccine, so it was assigned a score of 2. However, no clinical data exists to support its effectiveness as this is only in Phase 2 trials." - Anonymous Online Contributor